Table 3.
Comparison of Patient Characteristics Between Different Local Therapies
| Characteristics | Number of Patients (%) | p value | |||
|---|---|---|---|---|---|
| Radiotherapy (n = 29) | Surgery (n = 13) | Radiotherapy and Surgery (n = 14) | |||
| Age (years) | <50 | 4 (13.8) | 4 (30.8) | 6 (42.9) | 0.103 |
| ≥50 | 25 (86.2) | 9 (69.2) | 8 (57.1) | ||
| T stage | 1 | 11 (37.9) | 4 (30.8) | 4 (28.6) | 0.746 |
| 2 | 14 (48.3) | 7 (53.8) | 7 (50.0) | ||
| 3 | 4 (13.8) | 2 (15.4) | 3 (21.4) | ||
| pN stage | 0 | 7 (24.1) | 1 (7.7) | 4 (28.6) | 0.349 |
| 1 | 10 (34.5) | 5 (38.5) | 4 (28.6) | ||
| 2 | 6 (20.7) | 2 (15.4) | 4 (28.6) | ||
| 3 | 6 (20.7) | 5 (38.5) | 2 (14.3) | ||
| Breast surgery | Mastectomy | 25 (86.2) | 12 (92.3) | 12 (85.7) | 0.821 |
| BCS | 4 (13.8) | 1 (7.7) | 2 (14.3) | ||
| Pathology | IDC | 26 (89.7) | 12 (92.3) | 13 (92.9) | 0.927 |
| Others | 3 (10.3) | 1 (7.7) | 1 (7.1) | ||
| Histologic grade | 2 | 16 (55.2) | 7 (53.8) | 8 (57.1) | 0.985 |
| 3 | 13 (44.8) | 6 (46.2) | 6 (42.9) | ||
| Molecular subtype | Luminal | 9 (31.0) | 7 (53.8) | 7 (50.0) | 0.621 |
| HER2-enriched | 11 (37.9) | 3 (23.1) | 4 (28.6) | ||
| Triple-negative | 9 (31.0) | 3 (23.1) | 3 (21.4) | ||
| Adjuvant radiotherapy | Yes | 15 (51.7) | 8 (61.5) | 4 (28.6) | 0.190 |
| No | 14 (48.3) | 5 (38.5) | 10 (71.4) | ||
| Type of systemic therapy after ISLM | Only CT | 15 (51.7) | 8 (61.5) | 3 (21.4) | 0.315 |
| Only ET | 1 (3.4) | 1 (7.7) | 2 (14.3) | ||
| CT+ET | 6 (20.7) | 2 (15.4) | 6 (42.9) | ||
| CT+anti-HER2 drugs | 7 (24.1) | 2 (15.4) | 3 (21.4) | ||
Abbreviations: T, tumor; LN, lymph node; BCS, breast-conserving surgery; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2; ISLM, ipsilateral supraclavicular lymph node metastasis; CT, chemotherapy; ET, endocrine therapy.